VANRAYMI
Live / Applied — First extension granted (statement of use) (as of 03 Oct 2025)
What this means for you
Not registered yet, but its 27 Aug 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98719330
- Mark type
- Stylized text
- Filed
- 27 Aug 2024
- Published for opposition
- 01 Apr 2025
- Attorney of record
- Alexandra Kochian
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the prevention and treatment of cardiovascular diseases and diseases of the central nervous system; pharmaceutical preparations for the treatment of cancer, thrombosis, and respiratory diseases; pharmaceutical preparations for the treatment of rare diseases, namely, lysosomal storage disorders and autosomal dominant polycystic kidney disease; pharmaceutical preparations for the prevention and treatment of infectious diseases, namely, viral and bacterial infections
Owner
- Genzyme Corporation, Cambridge, MA, US
- Genzyme Corporation, Cambridge, MA, US
Prosecution history
- 04 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 03 Oct 2025 — SOU EXTENSION 1 GRANTED
- 03 Oct 2025 — SOU EXTENSION 1 FILED
- 03 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 26 Jun 2025 — TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
- 26 Jun 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 26 Jun 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 26 Jun 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 27 May 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 01 Apr 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 01 Apr 2025 — PUBLISHED FOR OPPOSITION
- 26 Mar 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 07 Mar 2025 — LAW OFFICE PUBLICATION REVIEW COMPLETED
- 07 Mar 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 07 Mar 2025 — EXAMINER'S AMENDMENT ENTERED